<DOC>
	<DOCNO>NCT00143130</DOCNO>
	<brief_summary>To evaluate long-term efficacy safety pregabalin ( 150 600mg/day ) adjunctive treatment patient partial seizure .</brief_summary>
	<brief_title>Pregabalin In Partial Seizures Extension Study</brief_title>
	<detailed_description />
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<criteria>meet inclusion/exclusion criterion A0081005 complete 21week study show significant clinical response wish continue treatment Having treatable cause seizure . Having progressive neurological systemic disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>phase 4 , open label , seizure , epilepsy , add-on therapy , pregabalin , lyrica</keyword>
</DOC>